For example, glioblastoma-derived immunomodulatory factors such as IL-6 and TGF-β have been implicated in the direct impairment of T-cell function and thus may limit the successful implementation of CAR-T therapy [68,69]. This evidence concerns the gene IL6 and glioblastoma.